Vor Biopharma updates investor presentation; no material new information disclosed

Vor Biopharma Inc.

Filed an updated corporate presentation under Item 8.01 on January 5, 2024.
Presentation reiterates ambition to cure blood cancers via cell and genome engineering.
No financial results, guidance, clinical data, or strategic updates were provided.
Exhibit 99.1 includes only a title slide; full content was not disclosed in the filing.
The update appears routine with no new business developments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.